Search hospitals > Minnesota > Saint Paul
Regions Hospital
Claim this profileSaint Paul, Minnesota 55101
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
477 reported clinical trials
24 medical researchers
Summary
Regions Hospital is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Regions Hospital is involved with conducting 477 clinical trials across 603 conditions. There are 24 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park8 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
104 reported clinical trials
167 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital6 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
61 reported clinical trials
110 drugs studied
Yan JiRegions Hospital2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
32 reported clinical trials
78 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park6 years of reported clinical research
Studies Cancer
Studies Relapse
14 reported clinical trials
19 drugs studied
Clinical Trials running at Regions Hospital
Lung Cancer
Prostate Cancer
Breast Cancer
Bladder Cancer
Breast cancer
Cancer
Multiple Myeloma
Esophageal cancer
Ovarian Cancer
Colorectal Cancer
Chemotherapy + Immunotherapy vs. Immunotherapy
for Advanced Lung Cancer
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab and chemotherapy may help stabilize lung cancer.
Recruiting2 awards Phase 3
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Regions Hospital?
Regions Hospital is a medical facility located in Saint Paul, Minnesota. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Regions Hospital is involved with conducting 477 clinical trials across 603 conditions. There are 24 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Where is Regions Hospital located?
**Regions Hospital Location and Directions:**
- **Address:** 640 Jackson Street, St. Paul, MN 55101.
- **Directions:**
- From I-35E South: Exit on University Avenue, turn right on University Avenue, then left on Jackson Street.
- From I-94 East: Exit at Marion Street, turn left on Marion Street, then right on University Avenue, and right on Jackson Street.
- From I-94 West or Highway 52 North to I-94 West: Exit at 12th Street, take an immediate right on Jackson Street.
- From I-35E North: Exit on 11th Street, turn left on Jackson Street.
Who should I call to ask about financial aid or insurance network?
For financial assistance and insurance inquiries at Regions Hospital:
- **Insurance Inquiries:** Call 651-254-1884.
- **General Financial Support:** Contact Patient Accounting Customer Service at 651-254-4791 (local) or 877-974-3600 (toll-free).
- **Financial Counselors:** Reach out at 651-254-0842 for further assistance.
- **Financial Assistance Application Questions:** Contact Patient Financial Services at 651-254-4791. The application is available online.
What insurance does Regions Hospital accept?
Regions Hospital accepts a wide range of insurance plans, including but not limited to Blue Cross and Blue Shield of Minnesota, Blue Plus, HealthPartners, Medicare, Aetna, and Affinity Medical Group. These plans often provide 100% coverage for preventive care, immunizations, eye exams, and prenatal/postnatal care. For specific coverage details and to confirm if your insurance is accepted, please contact the hospital directly or consult with your insurance provider.
What awards or recognition has Regions Hospital received?
Regions Hospital in Saint Paul, Minnesota, is a recipient of the Top 25 Environmental Excellence Award from Practice Greenhealth, marking it as a leader in environmental sustainability within healthcare. It has also earned the American Heart Association's Get With The Guidelines® Stroke Gold Plus achievement award, recognizing its adherence to core standards of stroke care with 85% or higher compliance over two years. Furthermore, the hospital extends its medical expertise to Minnesota Wild, St. Paul Saints, and Minnesota Vikings home games, providing on-site medical coverage and promoting health education.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.